Skip to content

PHARMALIXHE

Active Private limited companyfounded 2011active for 15 yearsRue de la Croix 13, 4600 ViséKBO/BCE: BE 0832.493.689

Lifetime

15 annual accounts with figures on one time axis
peak of €213,679 in 2022
€196,359▲ 1.8%
lowest -€36,626 in 2011
€24,699▼ 26.6%
peak of €293,509 in 2025
€293,509▲ 8.6%
€183,458▼ 1.8%
peak of 2.9 FTE in 2012
1.9 FTEunchanged
Board3 names since 2021
1 director
Documentsfilings and deeds
20-08-202620 days late
2025abbreviated format
Result from €33,648 to €24,699

Key points

from the 2025 annual accounts

Equity

€293,509 ▲ 8.6%

PHARMALIXHE has made a profit without a break since 2015.

Investments

€4,482 1.6 times depreciation
202120222025

Green is investment, beige is depreciation.

Staff

2 employees on 31-12-2025
222021112024332025

In 2025, 3 employees joined and 3 left.

2025 accounts filed 20 days after the deadline

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,726 companies had the same profile as PHARMALIXHE has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,726 companies, not a prediction for PHARMALIXHE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 01-01-2023
  • all the sharesdeed of 14-02-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0832493689
1 director appointed, 1 resignation resigns · appointed · acts as permanent representative · General meeting of 29-12-2022 · Gazette deed
appointed as director holds all the shares · General meeting of 20-01-2022 · Gazette deed
resigns as manager appointed as director · General meeting of 11-12-2021 · Gazette deed
All 27 events

Comparable companies

same main activity, similar in size and age
Company
PHARMALIXHE Visé €476,967 €196,359 61.5% 1.9
PHARMACIE SPITAELS Ixelles €510,941 €201,669 44.3% 2.1
PHARMASCHMIDT Liège €485,219 €225,840 40.4% 1.6
PHARMACIE DEMONCEAU Verviers €539,028 €228,344 65.9% 2.3
VERZELE PHARMA Oudenaarde €500,597 €186,426 33.2% 2
PHARMACIE QUERTON Anderlecht €442,937 €218,236 21.0% 1.6
PHAIES Ham-sur-Heure-Nalinnes €516,859 €219,804 31.0% 2

These companies have the same main activity as PHARMALIXHE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €443,000 and €539,000, founded between 2007 and 2012.

Official details

Source: KBO
Status
Active since 05-01-2011Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.196.884.3084600 Visé, since 05-01-2011
Financial year end
31 December
Peppol
Reachable since 20-11-2025
Company details

Annual accounts 2025

≈ €920,000estimated
€476,967▲ 4.3%
Employeeson 31-12-2025
2=
Filing
Filed on 20-08-2026
Financials

Insights on PHARMALIXHE

PHARMALIXHE files the abbreviated format. That format states no turnover. The gross margin rose from €140,115 in 2011 to €196,359 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PHARMALIXHE

What is the company number of PHARMALIXHE?
The company number of PHARMALIXHE is 0832.493.689. The VAT number is the same number with BE in front: BE 0832.493.689.
Where is PHARMALIXHE based?
The registered office is at Rue de la Croix 13, 4600 Visé.Company details
What does PHARMALIXHE do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PHARMALIXHE?
PHARMALIXHE is a private limited company (BV).
When was PHARMALIXHE founded?
PHARMALIXHE was founded on 05-01-2011.
Is PHARMALIXHE still active?
Yes, PHARMALIXHE is an active enterprise in the KBO register.
How many employees does PHARMALIXHE have?
PHARMALIXHE had an average of 1.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does PHARMALIXHE fall under?
In its 2025 annual accounts, PHARMALIXHE states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of PHARMALIXHE?
The turnover in financial year 2025 is ≈ €920,000. This figure is estimated from the gross margin of €196,359 and 43 comparable companies (NACE 477). It probably lies between €600,000 and €1.9m.
Is PHARMALIXHE profitable?
In financial year 2025, PHARMALIXHE made a profit of €24,699.
Where can I find the annual accounts of PHARMALIXHE?
PHARMALIXHE filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMALIXHE due?
PHARMALIXHE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.